Trial Profile

Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pexidartinib (Primary)
Indications Giant cell tumour of tendon sheath
Focus Registrational; Therapeutic Use
Acronyms PLX3397
Sponsors Daiichi Sankyo Company

Most Recent Events

26 Jun 2026 Planned End Date changed from 28 Feb 2026 to 31 Mar 2027.
12 Apr 2024 Planned End Date changed from 30 Mar 2024 to 28 Feb 2026.
04 Feb 2022 Planned End Date changed from 30 Mar 2022 to 30 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com